Dr Hannah Cohen

Dr Hannah CohenTel: 020 3447 9456
Fax: 020 3447 9911
Email: uclh.complexanticoagadminteam@nhs.net

Location:
University College Hospital

Specialities:
Blood Diseases (clinical haematology)

Professional background

I am a consultant haematologist, with a specialist interest in thrombosis and haemostasis. I am trust clinical lead for anticoagulation and venous thromboembolism; and clinical lead for the thrombosis and haemostasis service to Women’s Health at UCLH.

Research interests

My research interests include the pathophysiology, diagnosis and management of antiphospholipid syndrome, anticoagulation.

Publications

  • Cohen H, Arachchillage DJ, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing age. J Throm Haemost. In Press.
  • Wilson D, Charidimou A, Shakeshaft C, Ambler G, White M, Cohen H, Yousry T, Al-Shahi Salman R, Lip GY, Brown MM, Jäger HR, Werring DJ; CROMIS-2 collaborators. Volume and functional outcome of intracerebral haemorrhage according to oral anticoagulant type. Neurology. 2016;86:360-6.
  • The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods. Charidimou A, Wilson D, Shakeshaft C, Ambler G, White M, Cohen H, Yousry T, Al-Shahi Salman R, Lip G, Houlden H, Jäger HR, Brown MM, Werring DJ. Int J Stroke 2015;10 Suppl A100:155-61.
  • Efthymiou M, Lawrie AS, Mackie I, Arachchillage D, Lane PJ, Machin S, Cohen H. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. Thromb Res 2015 Jun;135:1191-7.
  • Arachchillage DR, Mackie IJ, Efthymiou M, Isenberg DA, Machin SJ, Cohen H. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost. 2015;13:1264-73.
  • Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res. 2015;135:388-93.
  • Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, Muirhead N; RAPS Trial Protocol Collaborators. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 2015;24:1087-94.
  • Cohen H, O’Brien P (Eds). Disorders of thrombosis and haemostasis in pregnancy: a guide to management. Second edition 2015. Springer.
  • Arachchillage DR, Machin SJ, Cohen H. Heparin-induced thrombocytopenia following plasma exchange in patients with demyelinating neurological disease. Int J Lab Hematol 2014; 37(4):e75-7. Nov 27.
  • Arachchillage DRJ, Mackie IJ, Machin SJ, Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost 2015;113:13-9.
  • Arachchillage DRJ, Efthymiou M, Lawrie AS, Machin SJ, Mackie IJ, Cohen H. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Haemost 2014;12:1801-9.
  • Romay-Penabad Z, Carrera Marin AL, Willis R, Weston-Davies W, Machin S, Cohen H, Brasier A, Gonzalez EB. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus. 2014;23:1324-6.
  • Erkan D, Aquiar C, Andrade D, Cohen H, Cuadrado M, Danowski A, Levy R, Ortel T, Rahman A, Salmon J, Tektonidou M, Willis R, Lockshin M. 14th Intrernational Congress in Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Autoimmunity reviews 2014;13(6):685-96.
  • Jayakody Arachchillage DR, Machin SJ, Cohen H. Antithrombotic treatment for stroke associated with antiphospholipid antibodies. Expert Rev Haematol 2014;7:169-172.
  • Arachchillage DRJ, Cohen H. Antiphospholipid Syndrome. Medicine 2014;42:156-161.
  • Arachchillage DR, Efthymiou M, Lawrie AS, Machin SJ, Mackie IJ, Cohen H. Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels. Thromb Haemost 2014;112(2).
  • Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013;163:303-14.Sep 14.
  • Arachchillage D and Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Current Rheumatology Reports 2013;15:331-5.
  • Bolton-Maggs PH, Davies T, Poles D, Cohen H. Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential haemovigilance scheme. Br J Obstet Gynaecol 2013;120:873-8.
  • Gardiner C, Hills J, Machin SJ, Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 2013;22:18-25.
  • Cohen H and Williamson LM. Setting up a National Haemovigilance System: shot. In: Haemovigilance. Eds RRP De Vries and J-C Faber. Wiley-Blackwell 2012; Part 3; chapter 14; p 168-179.
  • Cohen H, Bolton-Maggs P. Breaking records in blood transfusion safety. Transfusion Medicine 2012;22: 241-3.
  • Lawrie AS, Hills J, Longair I, Green L, Gardiner C, Machin SJ, Cohen H. The clinical significance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients. Thromb Res 2012;130:110-4.
  • Erkan D, Rahman A, Cohen H, Machin S, Pierangeli S. What are the potential new treatments in antiphospholipid syndrome? In Erkan D, and Pierangeli S. (Eds) Antiphospholipid Syndrome. Springer 2012.
  • Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011;118:1746-53.
  • Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus 2010;19:486-91.
  • Chaffe B, Jones J, Milkins C, Taylor C, Asher D, Glencross H, Murphy M, Cohen H. UK transfusion laboratory collaborative: recommended minimum standards for hospital transfusion laboratories. Trans Med 2009;19:156-8.
  • Chapman C, Stainsby D, Jones H, Love E, Massey E, Win N, Navarette C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009;49:440-52.
  • Cohen H, Gates C. Anticoagulation with dabigatran or rivaroxaban. Drugs and Therapeutics Bulletin 2009;47:116-20.
  • Gardiner C, Longair I, Pescott MA, Erwin H, Hills J, Machin SJ, Cohen H. Self-monitoring of oral anticoagulation: does it work outside trial conditions? J Clin Pathol 2009;62:168-171.
  • Quinn J, Von Klemperer K, Brooks R, Peebles D, Walker F, Cohen H. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience. Haematologica 2009;94:1608-12.
  • Camilleri RS, Cohen H, Mackie IJ, Scully M, Starke RD, Crawley JT, Lane DA, Machin SJ. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost 2008;6:331-8.
  • Gardiner C, Longair I, Hills J, Cohen H, Mackie IJ, Machin SJ. Performance evaluation of a new small-volume coagulation monitor: the SmartCheck INR system. Am J Clin Pathol 2008;129:500-4.
  • Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies. BMJ 1997;314:253-7.

GMC/GDC number: 2213383